title: Accuracy and progress in the analytics of pharmaceuticalization: a response to Davis (2014).
abstract: This commentary considers the important contribution to understanding pharmaceuticalization made by Davis's (2014) case study of cancer drug treatment in end-of-life-care. However, it argues that Davis (2014) has misunderstood some aspects of the conceptual and analytical framework put forward by Abraham (2010) as a way of explaining the nature and implications of pharmaceuticalization.
authors.affiliation: Dept of Social Science and Medicine, King's College London, The Strand, London, United Kingdom. Electronic address: john.w.abraham@kcl.ac.uk.
authors.forename: John
authors.initials: J
authors.lastname: Abraham
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007258:Informed Consent; D009369:Neoplasms / Q000188:drug therapy*; D000067490:Prescription Drug Overuse / Q000639:trends*; D013727:Terminal Care / Q000639:trends*; D019564:Unnecessary Procedures / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents
keywords: Analytical framework; Established health needs; Existing medicines; Pharmaceuticalization